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each tier, Porter suggests beginning measurement efforts with at least one outcome dimension per level, then expanding the number of dimensions and measures as feasible subject to availability of relevant data. 2 His approach to assessing value has been applied to breast cancer, knee osteoarthritis and type 2 diabetes. 1, 10 Others have provided further perspectives on the patient-centredness and practical challenges of implementing Porter's framework. [11] [12] [13] [14] Conventional approaches to assessing the impact of haemophilia health care have several limitations, including quantifying impacts on a narrow set of outcomes (eg number of joint bleeds) yet not their impact on, for example, overall patient health, family members or productivity. For example, they inadequately account for different impacts of prophylaxis vs. on-demand therapy in children and adults. 15, 16 Towards capturing this broader set of impacts, we adapted Porter's three-tiered outcomes hierarchy, designating outcomes within that hierarchy that are more likely to capture the range of patient experience across diverse patient subgroups and healthcare systems.
A multidimensional framework of haemophilia-specific outcomes was developed to better convey patient experience in haemophilia and enable decision-makers-from advocates to healthcare providers to national health authorities-to assess value of haemophilia care. With the objective of identifying and organizing patientcentred haemophilia outcomes, and recognizing that different decision-makers would use and weight outcomes differently subject to their respective remits, the framework does not assign relative weights. Emphasizing the patient experience, this framework currently accounts only for the numerator (outcomes) of the value equation, although it can be incorporated into value assessments with economic denominators.
| ME THODS
The International Haemophilia Access Strategy Council (IHASC)
consisted of four health economics and outcomes research experts from US, EU, and Asia, two haematologists specializing in haemophilia, one expert on payer perspective, and one representative of international haemophilia network and patient advocacy associations. Based on explicit patient orientation, ability to reflect multidimensional health impacts of diverse healthcare interventions, and previous application to other diseases, Porter's three-tiered hierarchy of outcome measures was selected as the basis for the haemophilia outcomes framework. Each tier and subsection of the framework was populated with outcome dimensions reflecting the haemophilia patient experience at individual and population levels. The outcomes were not scored or ranked; they were assigned according to their relevance to the framework tiers, to be applied depending on a user's purpose. Of particular importance to the council was to develop an outcomes framework of sufficient range to be sensitive to healthcare interventions regardless of delivery in high-, middle-or low-income countries, with varying access to standard haemophilia health care. Towards assessing its utility across interventions that may affect different patient outcomes, the proposed framework was applied to three clinical scenarios in haemophilia: (i) healthcare delivery, ie HTC vs. non-HTC; (ii) treatment regimen, ie primary prophylaxis vs. on-demand treatment;
and (iii) innovative therapies, ie standard replacement factor vs.
extended half-life (EHL) products. Figure 1 presents the proposed outcomes framework for haemophilia. 
| RE SULTS

| Development of the outcomes framework
| Tier 1-Health status achieved or retained
| Tier 2-Process of recovery
Porter defines Tier 2 as the time required to achieve recovery and return to normal function, and by disutility of care or treatment in terms of discomfort, retreatment, short-term complications, and errors and their consequences. 
| Tier 3-Sustainability of health
Sustainability of health refers to sustainability of overall health and recovery, including avoidance of recurrence of the original disease or longer-term complications and later-onset health problems that occur as a consequence of treatment. 2 In haemophilia, this tier embraces limiting breakthrough bleeding, joint preservation, lifelong productivity in the workplace, other contributions to society, and sustained good health based on high quality of life (QOL) and health utility. Long-term negative consequences may include long-term disutility of insufficient/inappropriate therapy and haemophilia-related complications associated with age-related comorbidities and other conditions that may arise with increased longevity.
Outcomes within and across the three tiers are not independent and are not intended to be combined into a quantitative index.
Consistent with Porter's description, improvement in an outcome in one dimension can benefit others. For example, reduction in serious bleeds can affect survival and HRQL in Tier 1, the risk of joint replacement in Tier 2 and lifelong productivity in Tier 3.
| Applicability for diverse scenarios
Applicability of the haemophilia outcomes framework, ie its ability to account for relevant patient-related outcomes, was examined in three highly relevant clinical scenarios: a healthcare delivery model (HTC vs non-HTC), a treatment regimen (prophylaxis vs. on-demand therapy) and an innovative therapy (EHL vs standard therapy) (Figure 2 ). on-demand treatment has led to its support by haemophilia organizations worldwide. [21] [22] [23] While increased use of factor for prophylaxis raises per-patient product costs compared to on-demand treatment, its impact on joint function preservation also reduces disability and non-factor healthcare costs among prophylaxis users. 24, 25 In assessing prophylaxis vs. on-demand treatment, the most prominent and evaluable outcome measures are under Tier 1, degree of health or recovery, and Tier 3, sustainability of health. Children with haemophilia receiving primary prophylaxis (vs on-demand) experience lower rates of joint bleeds and arthropathy and higher rates of normal index-joint structure, as well as less limitation of work or leisure, improvements in HRQL, improvements in school performance and reduced pain. 26, 27 No formal head-to-head comparisons of prophylaxis and on-demand therapy have been made for survival or life expectancy. Indirect evidence suggests that survival gains may accrue as a secondary effect of the primary outcome measure of reductions in serious bleeds. For example, primary prophylaxis is associated with reduced incidence of intracranial haemorrhage, which is associated with a 20% mortality rate and accounts for the greatest number of deaths from bleeding. For healthcare providers and payers, evidence of these impacts will help to assess any added value of haemophilia healthcare interventions and to inform efforts to reduce low-value services considered discretionary, unnecessary or harmful-thus freeing up budget for higher-value interventions. [28] [29] [30] Further, an outcomes framework that is widely accepted in the haemophilia community will assist industry to develop therapies and other interventions that are most meaningful to patients and substantiate their value to HTA agencies, payers, clinicians and patients. 27 For example, this framework can serve as a source of potential primary and secondary endpoints when designing clinical trials and other studies of haemophilia interventions.
| Healthcare delivery: HTC vs Non-HTC
Implementation of the framework will require (i) further review and validation by patient groups, (ii) development of data sources to support the evaluation of interventions' impact on outcomes in the framework and (iii) application of the framework to clinical trial design and other evaluations. Further, this initial framework could provide the basis for development of a standardized outcomes set for haemophilia, such as have been developed for various chronic and acute conditions. [32] [33] [34] Use of the framework for assessing the impacts of an intervention on a given patient group in a particular healthcare system depends on the availability and quality of relevant data. This includes findings from the carefully managed clinical trials that are typically used to gain regulatory approval of new therapies as well as from real-world data on outcomes and costs of these interventions in community settings. Based on available relevant health outcomes and economic evidence, decision-makers can apply their own methodologies, eg using incremental costeffectiveness ratios, to assess value. The haemophilia community must take the initiative to ensure that such evidence is generated and continually evaluate the need for adding or modifying outcomes in the framework. 
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